Results 151 to 160 of about 3,377,180 (268)

Early Weight Regain After GLP‐1 Receptor Agonist Discontinuation: Mechanisms and Implications for Treatment De‐Escalation Strategies

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8769-8776, October 2026.
ABSTRACT Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have transformed the pharmacological management of obesity, producing substantial and sustained weight loss during active treatment. However, discontinuation of therapy is frequently followed by significant weight regain, raising important questions regarding the durability of treatment ...
M. A. Damhof, F. H. van Bruggen, E. N. van Roon   +2 more
wiley   +1 more source

Renal Impairment Does Not Affect Pharmacokinetics, Safety or Tolerability of Zenagamtide

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 8946-8954, October 2026.
ABSTRACT Aims Zenagamtide is a novel, unimolecular glucagon‐like peptide‐1 and amylin receptor agonist in development for weight management and Type 2 diabetes. This study investigated the pharmacokinetic (PK) properties, safety and tolerability of zenagamtide in participants with various degrees of renal impairment versus participants with normal ...
Lykke Ida Kaas Oldenburg, Sine Pfeiffer Haugaard, Tobias Karlsson, Victoria Kegel‐Hübner, Mahera Parwez, Christoffer Wiingaard, Anne Flint   +6 more
wiley   +1 more source

Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9317-9325, October 2026.
ABSTRACT Aims To assess the added value of absolute anthropometric targets alongside percentage weight loss in the clinical management of obesity. Materials and Methods The phase 3a, 68‐week REDEFINE 1 trial randomised adults without diabetes with BMI ≥ 30 kg/m2, or ≥ 27 kg/m2 with ≥ 1 obesity‐related complication, to once‐weekly CagriSema 2.4 mg/2.4 ...
Luca Busetto, Cynthia Osorto Contreras, Mikkel Hovden Christensen, Timothy W. Garvey, Deborah B. Horn, Barbara McGowan, Claire Prener Miller, Volker Schnecke, Carel W. le Roux   +8 more
wiley   +1 more source

Bioactive Properties of Achillea biserrata M.Bieb. Extracts: Phytochemical Analysis, Antioxidant Activity, Target Enzyme Inhibition, and Cytotoxic Effects

Chemistry &Biodiversity, Volume 23, Issue 9, September 2026.
Integrated evaluation of Achillea biserrata extracts combining LC‐MS/MS phytochemical profiling, antioxidant, enzyme inhibitory, and antiproliferative assays with multivariate chemometric analyses (Pearson correlation, PCA, hierarchical clustering, and PLS regression), revealing phytochemicals associated with the observed biological activities (The ...
Zühal Bayrakçeken Güven, Mustafa Abdullah Yilmaz, Huseyin Inceer   +2 more
wiley   +1 more source

The longevity dividend: Why governments and markets must catch up

Experimental Physiology, EarlyView.
Nikodem Grzesiak, Serena Kern‐Libera, Richard Faragher, Annalisa Jenkins, Guy Coughlan, Damian Miles Bailey, Carina Kern   +6 more
wiley   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, Volume 12, Issue 3, Page 183-196, September 2026.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Recent advances in incretin biology and therapeutics: From glucose-dependent insulinotropic polypeptide reappraisal to next-generation agonists. [PDF]

J Diabetes Investig
Kubota S, Seino Y, Yabe D.
europepmc   +1 more source

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi, Mohammad Irshad, Jumana Alkandri, Anant Mashankar, Stuart R. Gray, Carel W. le Roux   +5 more
wiley   +1 more source

Genetic variants of glucose-dependent insulinotropic polypeptide (GIP) signalling as proxy for body weight reduction and cardiovascular risk. [PDF]

Eur Heart J
Emanuelsson F, Nordestgaard BG, Benn M.
europepmc   +1 more source

Combination Pharmacotherapies for Obesity—Current Evidence and Future Directions

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
A. B. M. Kamrul‐Hasan, Arnav Kalra, Nitin Kapoor, Deep Dutta, Kunal Mahajan, Robin Maskey, Syed Abbas Raza   +6 more
wiley   +1 more source